Expression of osteopontin in invasive breast carcinoma and its relationship with microvessel density

doi:10.3877/cma.j.issn.1674-0807.2011.04.006

Abstract

Abstract:

Objective

To explore the expression of osteopontin in breast carcinoma and its relationship with microvascular density.

Methods

Envision immunohistochemical method was used to examine the expressions of osteopontin and CD34 in 89 invasive breast carcinoma cases and analyze their relationship with clinical pathological characteristics.Qualitative data were analyzed using chi-square test. Quantitative data were analyzed using t test.

Results

In the 89 cases of breast invasive ductal carcinoma,the positive rate of osteopontin was 57.30% (51/89). In grade I, II and III invasive ductal carcinoma patients,the positive rate of osteopontin was 27.27%(6/22), 66.67% (24/36) and 67.74%(21/31), respectively, with statistically significant difference between the three groups of patients(χ²=10.780,P=0.005). In patients with lymph nodes metastases and without lymph nodes metastases, the positive rate of osteopontin was 74. 47% (35/47) and 38. 10% (16/42)respectively, showing a high positive rate of osteopontin patients with lymph nodes metastases than without (χ²=11.993,P=0.001). The microvessel density was (68.42±23.45) per high-power field in patients with negative expression of osteopontin and (94.96±31.03)per high-power field in patients with positive expression of osteopontin, with statistically significant difference between the two groups (t=4.413, P=0.000).

Conclusion

High expression of osteopontin in breast cancer may have some relationship with tumor angiogenesis and tumor invasion and metastasis. Further study on the role of osteopontin in breast cancer blood vessels will provide a new method for the clinical treatment of breast cancer metastasis.

Key words: osteopontin, CD34, breast carcinoma, microvessel density, immunohistochemistry

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0807.2011.04.006

https://zhrxbzz.cma-cmc.com.cn/EN/Y2011/V05/I04/426

Figures/Tables 6

References 17

[1]	邵志敏.乳腺癌外科治疗发展趋势[J].外科理论与实践,2006, 11(2):89-91.
[2]	Senger DR, Wirth DF, Hynes RO, et al. Transformed mammalian cells secrete specific proteins and phosphoproteins[J].Cell,1979,16(4):885-893.
[3]	Weindner N,Folkman J,Pozza F,et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma[J]. J Nail Cancer Inst,1992,84(24):1875-1887.
[4]	Rudland PS, Higgins AP, Tanani ME, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer [J].Cancer Res,2002,62(12):3417-3427.
[5]	Bramwell VH, Doig GS, Tuck AB, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer[J]. Clin Cancer Res,2006,12(7):3337-3343.
[6]	Allan AL, George R, Vantyghem SA, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer[J]. Am J Pathol,2006,169(1): 233-246.
[7]	EI Tanani M, Barraclough R, Wilkinson MC, et al.Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tef-4[J]. Cancer Res,2001, 61(14):5619-5629.
[8]	Mi ZY, Guo HT, Philip Y, et al. Integrin linked kinase regulates oesteopontin dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells[J]. Carcinogenesis,2006,27(6):1134-1145.
[9]	Tang H, Wang J, Bai F,et al. Inhibition of osteopontin would suppress angiogenesis in gastric cancer[J]. Biochem Cell Biol,2007,85(1):103-110.
[10]	Jain S, Chakraborty G, Kundu GC. The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis [J]. Cancer Res, 2006,66(13):6638-6648.
[11]	Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms[J]. Cancer Res,2008,68(1):152-161.
[12]	Cavallam U, Christofori G. Molecular mechanisms of tumor angiogenesis and tumor progression[J]. Neuro Oncol,2000,50(1/2):63-70.
[13]	孟令华,刘巍,宋丽楠,等.BCSG1、C-erbB-2、VEGF 表达与乳腺癌临床病理因素相关性研究[J/CD].中华乳腺病杂志:电子版,2007,1(4):29-36.
[14]	Hirama M, Takahashi F, Takahashi K, et al .Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth [J]. Cancer Lett, 2003,198(1):107-117.
[15]	Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms[J]. Cancer Res,2008,68(1):152-161.
[16]	Takahash F, Akatagawa S, Fukumoto H, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice[J]. Int J Cancer,2002,98(5):707-712.
[17]	Cheriyath V,Hussein MA.Osteopontin,angiogenesis and multiple myeloma[J].Leukemia,2005,19(12):2203-2205.

临床特征	例数	OPN[例(%)]		χ²值	P值
临床特征	例数	阳性	阴性	χ²值	P值
年龄				0.794	0.373
≤50	66	36(54.55)	30(45.45)
＞50	23	15(65.22)	8(34.78)
肿瘤大小				0.673	0.412
≤2	30	19(63.33)	11(36.67)
＞2	59	32(54.24)	27(45.76)
组织学分级				10.780	0.005
Ⅰ级	22	6(27.27)^a	16(72.73)
Ⅱ级	36	24(66.67)	12(33.33)
Ⅲ级	31	21(67.74)	10(32.26)
淋巴结				11.993	0.001
无	42	16(38.10)	26(61.90)
有	47	35(74.47)	12(25.53)

临床特征	例数	OPN[例(%)]		χ²值	P值
临床特征	例数	阳性	阴性	χ²值	P值
年龄				0.794	0.373
≤50	66	36(54.55)	30(45.45)
＞50	23	15(65.22)	8(34.78)
肿瘤大小				0.673	0.412
≤2	30	19(63.33)	11(36.67)
＞2	59	32(54.24)	27(45.76)
组织学分级				10.780	0.005
Ⅰ级	22	6(27.27)^a	16(72.73)
Ⅱ级	36	24(66.67)	12(33.33)
Ⅲ级	31	21(67.74)	10(32.26)
淋巴结				11.993	0.001
无	42	16(38.10)	26(61.90)
有	47	35(74.47)	12(25.53)

骨桥蛋白表达	例数	MVD(条/HP)	t值	P值
阳性	51	94.96±31.03	4.413	0.000
阴性	38	68.42±23.45

骨桥蛋白表达	例数	MVD(条/HP)	t值	P值
阳性	51	94.96±31.03	4.413	0.000
阴性	38	68.42±23.45

Please choose a citation manager

Content to export